Tests for liver scar (fibrosis) in children after liver transplant
Part of Digestive system clinical trials.
This study checks how well a liver “fibrosis panel” test can evaluate scarring in children who have had their first liver transplant. Your child may be helped by getting extra monitoring of liver scarring, and the study may improve how doctors assess recovery and risk over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 8 weeks and 18 years old
- Your child received a first liver transplant (living or deceased donor)
- The transplant was only for the liver (not heart/lung/kidney too)
- A parent or guardian can understand the study and signs consent
- Your child does not have pregnancy or breastfeeding concerns
- Your child has no serious ongoing whole-body infection right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether children who had a liver transplant before age 6 can safely stop taking their anti-rejection medicine. It's for children who are doing well — with normal liver function and no signs of rejection or scarring — at least 4 years after transplant.
This study tracks how babies grow and develop after receiving a liver transplant. Researchers want to understand how transplantation affects children's physical growth and overall development in early infancy.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.